297 related articles for article (PubMed ID: 18559778)
1. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
2. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.
Bhutani T; Koo J
J Dermatolog Treat; 2011 Apr; 22(2):75-8. PubMed ID: 20524874
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
Bissonnette R; Bolduc C; Poulin Y; Guenther L; Lynde CW; Maari C
J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
[TBL] [Abstract][Full Text] [Related]
5. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
6. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
7. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
8. Treatment of inflammatory immunologic disease 3. Anti-TNF therapy in rheumatoid arthritis.
Takeuchi T
Intern Med; 2007; 46(16):1311-2. PubMed ID: 17704613
[No Abstract] [Full Text] [Related]
9. Disease control for patients with psoriasis receiving continuous versus interrupted therapy with adalimumab or etanercept: a clinical practice study.
Moreno-Ramírez D; Ojeda-Vila T; Ferrándiz L
Am J Clin Dermatol; 2014 Dec; 15(6):543-9. PubMed ID: 25217234
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the tumor necrosis factor antagonists.
Bachmann F; Nast A; Sterry W; Philipp S
Semin Cutan Med Surg; 2010 Mar; 29(1):35-47. PubMed ID: 20430306
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
[TBL] [Abstract][Full Text] [Related]
15. A review of biologic treatments for psoriasis with emphasis on infliximab.
Pirzada S; Tomi Z; Gulliver W
Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
[TBL] [Abstract][Full Text] [Related]
16. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
17. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
18. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Smith CH; Anstey AV; Barker JN; Burden AD; Chalmers RJ; Chandler D; Finlay AY; Griffiths CE; Jackson K; McHugh NJ; McKenna KE; Reynolds NJ; Ormerod AD;
Br J Dermatol; 2005 Sep; 153(3):486-97. PubMed ID: 16120132
[No Abstract] [Full Text] [Related]
19. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
20. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors.
Chen M; Holland MJ; Mir MR; Wong MG; Kelley BP; Grim KD; Bhuchar SS; Hsu S
J Drugs Dermatol; 2011 Mar; 10(3):280-4. PubMed ID: 21369645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]